TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION

Docket Number

In re Application of: Ellen M. Heath et al.

Application No.: 09/974,798

Filed: October 12, 2001

For: COMPOSITIONS AND METHODS FOR USING A SOLID SUPPORT TO PURIFY RNA

The owner", <u>Qiagen North American Holdings, Inc.</u>, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patient granted on the instant application which would extend beyond the expiration date of the full statutory term of any patient granted on pending reference Application Number 11/589,384. (fied on <u>Qictober 30</u>, 2006, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patient granted on said reference application may be shortened by any terminal disclaimer field prior to the grant of any patient on the pending reference application. The owner hereby agrees that any patient so granted on the instant application shall be enforceable only for and during such perior that it and any patient granted to the reference application are commonly owned. This agreement runs with any patient granted on the instant application and is binding upon the grantee it is successors or assisting.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S. C. 154 and 173 or application. The strength of the statutory term as defined in 35 U.S. C. 154 and 173 or application. The proposition of the strength of the strengt

Check either box 1 or 2 below, if appropriate.

 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. X The undersigned is an attorney or agent of record. Registration No. 53.937

/Qing Lin/	June 4, 2009
Signature	Date
Qing Lin, Ph.D.	
Typed or printed name	_
(206) 622-4900	
Telephone Number	

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.